TY - JOUR
T1 - Vitamin-mineral treatment improves aggression and emotional regulation in children with ADHD
T2 - a fully blinded, randomized, placebo-controlled trial
AU - Rucklidge, Julia J.
AU - Eggleston, Matthew J.F.
AU - Johnstone, Jeanette M.
AU - Darling, Kathryn
AU - Frampton, Chris M.
N1 - Funding Information:
The authors thank the Vic Davis Memorial Trust (E5672), UC Foundation, the Department of Psychology, University of Canterbury for ongoing research support, the GAMA Foundation, Canterbury Medical Research Foundation, Foundation for Excellence in Mental Health Care, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH) T32 AT002688 to support JJ and a PhD Scholarship awarded through Gravida to support KD. They thank also David Pugh-Williams for assistance with randomization; Leona Manna for providing cultural consultation; Lucy Kioa, Kate Harris, Anna Lee, Joanna Lothian, Hannah Retallick-Brown, Dr Brigette Gorman, Dr Heather Gordon and Molly Harvie for assistance with data collection and entry; the Canterbury District Health Board, Whakatata House and other private referrers and all the families who participated. They thank Hardy Nutritionals for providing the micronutrient formula and matching placebo for free. The 48-ingredient formula has been modified slightly on several occasions, with each change resulting in a new name. Sold variously as Daily Essential Nutrients, EMPowerplus Advanced and Q96. The authors have declared that they have no competing or potential conflicts of interest.
Publisher Copyright:
© 2017 Association for Child and Adolescent Mental Health.
PY - 2018/3
Y1 - 2018/3
N2 - Background: Evaluation of broad-spectrum micronutrient (vitamins and minerals) treatment for childhood ADHD has been limited to open-label studies that highlight beneficial effects across many aspects of psychological functioning. Method: This is the first fully blinded randomized controlled trial of medication-free children (n = 93) with ADHD (7–12 years) assigned to either micronutrients (n = 47) or placebo (n = 46) in a 1:1 ratio, for 10 weeks. All children received standardized ADHD assessments. Data were collected from clinicians, parents, participants and teachers across a range of measures assessing ADHD symptoms, general functioning and impairment, mood, aggression and emotional regulation. Results: Intent-to-treat analyses showed significant between-group differences favouring micronutrient treatment on the Clinical Global Impression-Improvement (ES = 0.46), with 47% of those on micronutrients identified as ‘much’ to ‘very much’ improved versus 28% on placebo. No group differences were identified on clinician, parent and teacher ratings of overall ADHD symptoms (ES ranged 0.03–0.17). However, according to clinicians, 32% of those on micronutrients versus 9% of those on placebo showed a clinically meaningful improvement on inattentive (OR = 4.9; 95% CI: 1.5–16.3), but no group differences on improvement in hyperactive-impulsive symptoms (OR = 1.0; 95% CI: 0.4–2.5). Based on clinician, parent and teacher report, those on micronutrients showed greater improvements in emotional regulation, aggression and general functioning compared to placebo (ES ranged 0.35–0.66). There were two dropouts per group, no group differences in adverse events and no serious adverse events identified. Blinding was successful with guessing no better than chance. Conclusions: Micronutrients improved overall function, reduced impairment and improved inattention, emotional regulation and aggression, but not hyperactive/impulsive symptoms, in this sample of children with ADHD. Although direct benefit for core ADHD symptoms was modest, with mixed findings across raters, the low rate of adverse effects and the benefits reported across multiple areas of functioning indicate micronutrients may be a favourable option for some children, particularly those with both ADHD and emotional dysregulation. Trial registered with the Australian New Zealand Clinical Trials Registry ACTRN12613000896774.
AB - Background: Evaluation of broad-spectrum micronutrient (vitamins and minerals) treatment for childhood ADHD has been limited to open-label studies that highlight beneficial effects across many aspects of psychological functioning. Method: This is the first fully blinded randomized controlled trial of medication-free children (n = 93) with ADHD (7–12 years) assigned to either micronutrients (n = 47) or placebo (n = 46) in a 1:1 ratio, for 10 weeks. All children received standardized ADHD assessments. Data were collected from clinicians, parents, participants and teachers across a range of measures assessing ADHD symptoms, general functioning and impairment, mood, aggression and emotional regulation. Results: Intent-to-treat analyses showed significant between-group differences favouring micronutrient treatment on the Clinical Global Impression-Improvement (ES = 0.46), with 47% of those on micronutrients identified as ‘much’ to ‘very much’ improved versus 28% on placebo. No group differences were identified on clinician, parent and teacher ratings of overall ADHD symptoms (ES ranged 0.03–0.17). However, according to clinicians, 32% of those on micronutrients versus 9% of those on placebo showed a clinically meaningful improvement on inattentive (OR = 4.9; 95% CI: 1.5–16.3), but no group differences on improvement in hyperactive-impulsive symptoms (OR = 1.0; 95% CI: 0.4–2.5). Based on clinician, parent and teacher report, those on micronutrients showed greater improvements in emotional regulation, aggression and general functioning compared to placebo (ES ranged 0.35–0.66). There were two dropouts per group, no group differences in adverse events and no serious adverse events identified. Blinding was successful with guessing no better than chance. Conclusions: Micronutrients improved overall function, reduced impairment and improved inattention, emotional regulation and aggression, but not hyperactive/impulsive symptoms, in this sample of children with ADHD. Although direct benefit for core ADHD symptoms was modest, with mixed findings across raters, the low rate of adverse effects and the benefits reported across multiple areas of functioning indicate micronutrients may be a favourable option for some children, particularly those with both ADHD and emotional dysregulation. Trial registered with the Australian New Zealand Clinical Trials Registry ACTRN12613000896774.
KW - ADHD
KW - Mood
KW - Treatment
KW - aggression
KW - micronutrient
KW - mineral
KW - vitamin
UR - http://www.scopus.com/inward/record.url?scp=85030453678&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030453678&partnerID=8YFLogxK
U2 - 10.1111/jcpp.12817
DO - 10.1111/jcpp.12817
M3 - Article
C2 - 28967099
AN - SCOPUS:85030453678
SN - 0021-9630
VL - 59
SP - 232
EP - 246
JO - Journal of Child Psychology and Psychiatry and Allied Disciplines
JF - Journal of Child Psychology and Psychiatry and Allied Disciplines
IS - 3
ER -